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ABSTRACT
Introduction: Traditional clinical trials inpsoriasis
exclude a significant proportion of patients with
complex disease and comorbidities. A consensus
panel of 14 experts in the field of psoriasis was
formed to conduct a Delphi method exercise to
identify difficult-to-treat psoriasis clinical
scenarios and to rank treatment approaches.
Methods: The exercise consisted of both survey
questionnaires and a live meeting to review and
discuss current data (as of 2009, when the
exercise was conducted) and arrive at a
consensus for optimal treatment options.
B. E. Strober (&)
Department of Dermatology, University of




Division of Dermatology, Department of Internal
Medicine, Baylor University Medical Center, and
Modern Dermatology, Dallas, TX, USA
D. Cohen
Department of Dermatology, NYU Langone Medical
Center, New York, USA
J. J. Crowley
Bakersfield Dermatology and Skin Cancer Medical
Group, Bakersfield, CA, USA
K. B. Gordon
Department of Dermatology, Northwestern
University Feinberg School of Medicine,
Chicago, IL, USA
A. B. Gottlieb  J. M. Sobell
Department of Dermatology, Tufts Medical Center
and Tufts University School of Medicine, Boston,
MA, USA
A. F. Kavanaugh
Division of Rheumatology, Allergy, and
Immunology, Department of Medicine,
University of California, San Diego, CA, USA
N. J. Korman
Department of Dermatology, Case Western Reserve
University School of Medicine, Cleveland, OH, USA
G. G. Krueger
Department of Dermatology, University of Utah,
Salt Lake City, UT, USA
C. L. Leonardi
Department of Dermatology, St. Louis University
School of Medicine, St. Louis, MO, USAEnhanced content for this article is
available on the journal web site:
www.dermtherapy-open.com
123
Dermatol Ther (2012) 2:1
DOI 10.1007/s13555-012-0001-y
Seventy difficult treatment scenarios were
identified, and the top 24 were selected for
discussion at the live meeting.
Results: Six of the 24 discussed case scenarios
are presented in this article (another five are
presented in Part 2): (1) psoriasis with human
papilloma virus-induced cervical or anogenital
dysplasia; (2) concomitant psoriasis and
systemic lupus erythematosus; (3) severe
psoriatic nail disease causing functional or
emotional impairment; (4) psoriasis therapies
that potentially reduce cardiovascular morbidity
and mortality; (5) older patients (C65 years of
age) with psoriasis; and (6) severe scalp psoriasis
that is unresponsive to topical therapy.
Conclusion: The Delphi exercise resulted in
guidelines for practicing physicians to utilize when
confrontedwithchallengingpatientswithpsoriasis.
Keywords: Acitretin; Biologics; Methotrexate;
Psoriasis; Psoriatic nail disease; Severe scalp
psoriasis; TNF-a inhibitor
INTRODUCTION
In an effort to provide treatment guidance
regarding a selected group of complex psoriasis
scenarios, individuals with a specific interest in
psoriatic disease formed a consensus panel and
carried out a Delphi exercise. Because the published
clinical trials for psoriasis therapeutics typically
enroll healthy patients without comorbidity or
other complex clinical features (e.g., concomitant
lupus erythematosus, significant cardiovascular
disease, human papilloma virus [HPV]-induced
cervical or anogenital dysplasia, or human
immunodeficiency virus [HIV] infection), other
sources are needed to guide therapy for these
patient types.
The Delphi method is particularly well suited
for addressing healthcare-related issues because
the outcome represents the collective judgment of
the panel of experts on selected topics. The Delphi
method includes three basic characteristics:
(1) repeated individual questioning of the
experts; (2) the avoidance of direct confrontation
among the experts (e.g., anonymity); and
(3) interspersed controlled opinion and feedback.
Importantly, the Delphi method seeks to achieve
consensus on complex scenarios where rigorous
data are lacking. Availabledataon a given topicare
reviewed extensively, presented, and discussed
among the panelists. More importantly, by
employing only anonymous voting by the
panelists, the Delphi method settles controversy
by eliminating the effects of either reputation or
‘‘personality.’’ Consequently, anonymous voting
after thorough review of the data allows the
panelists to vote for what they truly believe, thus
avoiding ‘‘groupthink’’ and sentiment guided
more by ‘‘eminence,’’ charisma, and dogmatism.
What follows is an application of the Delphi
method for difficult-to-treat clinical scenarios in
patients with moderate-to-severe psoriasis. This
process occurred in the following three steps
over approximately 5 months: (1) selection of
difficult-to-treat psoriasis clinical scenarios;
(2) selection of potential psoriasis treatment
modalities; and (3) the matching, through
systematic, iterative rounds of voting, of the
clinical scenarios with the most appropriate
treatments based on informed assessment of the
peer-reviewed literature. At all times, the votes
of the individual panelists were kept
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anonymous; thus, at no point was a single
individual able to direct the outcome of any
aspect of this process. What follows is a
reiteration of a process first implemented in
2008 [1].
METHOD OVERVIEW
This Delphi exercise began with the
identification of 14 experts in the field of
psoriasis by virtue of their publication record,
participation in national meetings, interest in
treating psoriasis and psoriatic arthritis, and
participation in clinical trials and basic research
on psoriatic disease. All experts come from the
United States (US). Next, without guidance, the
individual panelists were asked to list both
challenging clinical scenarios and therapeutic
options for psoriasis. Through a series of survey
questionnaires and anonymous feedback by the
participants, clinical scenarios were selected and
ranked, and the treatment options were listed.
The top-ranked 24 clinical scenarios were
then assigned to the panelists for the preparation
of a PowerPoint review of the available peer-
reviewed data that supported the use of specific
treatment approaches. Each panelist presented his
or her assigned clinical scenarios along with the
supporting data for the various treatments at a live
meeting held on January 22, 2009. After each
presentation, a structured and time-limited
discussion and debate occurred. A final round of
anonymous, electronic voting determined the
ultimate ranking of treatment choices for each
clinical scenario.
Identification Process
The panelists generated a preliminary set of
70 difficult treatment scenarios based on their
clinical expertise and experience (Fig. 1). Next,
each scenario was anonymously ranked on a
five-point scale ranging from ‘‘very important’’
to ‘‘unimportant.’’ From this process, 24 top-
ranked scenarios (by virtue of being ranked
more important) were selected (Table 1).
Each panelist was asked to anonymously
submit a list of treatments for psoriasis
and/or psoriatic arthritis (Food and Drug
Administration [FDA] approved, off-label, or
investigational yet near likely approval). From
this effort, a list of 60 potential treatments was
generated (Table 2). Next, the panelists were
asked to anonymously list, according to their
knowledge of the literature and personal
experience, the five most appropriate
treatment options (chosen from the ‘‘master’’
list of 60 treatments) for each of the
24 challenging clinical scenarios. The results of
a statistical compilation of the voting from all
14 panelists generated a list of the top-10
treatment options for each clinical scenario.
These top-10 options were presented to the
panelists, who then ranked each of the
10 options on a scale of 1 (most appropriate)
to 10 (least appropriate). This second round of
voting thus created an updated, ranked list of
treatments for each clinical scenario for the live
meeting. Of note, this discussion occurred prior
to the voluntary withdrawal of efalizumab from
the market, so in cases where efalizumab ranked
in the top-10 treatment options it was removed.
Live Meeting
A live meeting was scheduled to discuss the 24 top-
ranked difficult treatment scenarios. Each panelist
was assigned one or more clinical scenarios to
present. Panelists were assembled in a conference
room around a horseshoe-shaped table.
During each 15-min presentation, the panelist
offered evidence-based data regarding the safety
and efficacy of most, if not all, of the top-10
ranked treatment options determined by the
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previous round of voting. A 15-min discussion
and debate with the other participants followed,
during which each of the non-presenting
participants were given 1 min to make concise
points regarding their views of the presented data
and treatment preferences. Using an anonymous
audience response system (ARS; TurningPoint
Technologies, Youngstown, OH, USA), all
panelists participated in the final round of
voting, re-ranking the 10 choices based on their
Fig. 1 The Delphi process used to identify and rank
treatment options for challenging psoriasis case scenarios.
*These discussions occurred before the voluntary with-
drawal of efalizumab from the US market. In cases in which
efalizumab ranked among the top treatment options, it has
been eliminated. ?Six of the cases are presented in this
article
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final assessment of the data. Importantly,
treatments that were previously not listed in the
top 10couldnotbeadded during the livemeeting.
Real-time tabulation and viewing of the final
rankings occurred. Panelists also recorded their
rankings in a workbook, which allowed
confirmation of the electronically acquired data.
After the final ranking, if a treatment option
was thought to be medically inappropriate for a
given scenario, individual panelists were
Table 1 The 24 selected topics from the 2009 Psoriasis Consensus Conference
Psoriasis therapies that potentially reduce cardiovascular morbidity and mortality
Palmoplantar psoriasis, unresponsive to topical therapy and phototherapy
Preferred therapeutic choice when combining with low-dose methotrexate
Prior history of nonmelanoma skin cancer (SCC and BCC)
Obese patients with psoriasis and/or psoriatic arthritis
Older patients (C65 years of age)
Patients with severe psoriasis and psoriatic arthritis who have recurrent infections on any anti-TNF therapy
Newly pregnant women who are currently receiving and responding well to a TNF inhibitor
Psoriasis plus the metabolic syndrome
Severe psoriatic nail disease causing functional or emotional impairment
Erythrodermic psoriasis
Severe scalp psoriasis, unresponsive to topical therapy
Psoriatic arthritis
Treatment for new-onset psoriasis (of any morphology) in patients undergoing anti-TNF therapy for another immune-
mediated inﬂammatory disease (e.g., inﬂammatory bowel disease or RA)
Pustular psoriasis
Patients who are already receiving potentially immunosuppressive therapy other than methotrexate
Moderate-to-severe psoriasis that has failed to respond to all currently approved therapies for psoriasis in patients who
cannot receive methotrexate or cyclosporine A
Patients with psoriasis and/or psoriatic arthritis who develop neurologic symptoms or signs after starting a TNF-
inhibitor, and then fail appropriate trials of methotrexate and T-cell inhibitors (alefacept and efalizumab)
Patients who never respond to or initially respond to then fail all available TNF inhibitors (essentially, treatment for
TNF-resistant or -unresponsive patients)
Patients with a history of a solid tumor malignancy
Inverse psoriasis, unresponsive to topical therapy
Psoriasis plus HPV-induced cervical or anogenital dysplasia
Psoriasis with concomitant systemic lupus erythematosus
Psoriasis in patients B16 years of age
BCC basel cell carcinoma, HPV human papilloma virus, RA rheumatoid arthritis, SCC squamous cell carcinoma, TNF
tumor necrosis factor
Dermatol Ther (2012) 2:1 Page 5 of 24
123
Table 2 Potential psoriasis treatment options generated during the Delphi process
6-mercaptopurine 6-thioguanine 6-thioguanine plus biologic
therapy
6-thioguanine plus phototherapy Abatacept Acitretin
Acitretin ? biologic therapy Acitretin ? hydroxyurea Adalimumab
Alefacept Anthralin Azathioprine
Certolizumab (pegylated fab fragment
against TNF)
COX-2 inhibitors Crude coal tar
Cyclosporine Efalizumaba Etanercept
Excimer laser Hydroxychloroquine Hydroxyurea
Inﬂiximab Intra-articular corticosteroids Intralesional corticosteroids
Leﬂunomide LCD Methotrexate plus alefacept
Methotrexate plus efalizumab MTX MTX plus a TNF inhibitor
MTX plus cyclosporine Mycophenolate mofetil Natural UV light
NSAID Sulfasalazine Systemic corticosteroids
TACR olimus (oral formulation) TNF inhibitor (adalimumab preferred
more than the other two available
drugs of this class)
TNF inhibitor (etanercept preferred
more than the other two available
drugs of this class)
TNF inhibitor (inﬂiximab preferred
more than the other two available
drugs of this class)
TNF inhibitor (without concern for
any individual drug)
TNF inhibitor plus cyclosporine
Tocilizumab (humanized monoclonal
antibody against IL-6r)
Topical calcipotriene Topical calcitriol
Topical corticosteroid in combination
with calcipotriene





Topical tazarotene Topical tazarotene ? topical
corticosteroid
UV phototherapy—broadband b UV phototherapy—narrow band b UV phototherapy—PUVA
UV phototherapy plus acitretin UV phototherapy plus biologic UV phototherapy plus LCD, crude
coal tar, or anthralin (Goeckerman,
Ingram)




As a ﬁrst choice, no therapy should be
given in this scenario
COX-2 cyclooxygenase 2, IL interleukin, LCD liquid carbonis detergens, MTX methotrexate, NSAID nonsteroidal anti-
inﬂammatory drug, PUVA psoralen ? UVA phototherapy, TNF tumor necrosis factor, UV ultraviolet
a Removed from the US market in 2009
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allowed to ‘‘challenge’’ the inclusion of the
potentially inappropriate treatment. The
challenging panelist was given 1 min to
support his or her case for elimination of
a therapy. Subsequently, two opposing
arguments presented by two different
panelists against the challenge were allowed,
each 1 min in length. In these scenarios,
another round of anonymous voting
occurred. A listed therapy was eliminated as a
treatment option only if a two-thirds majority
(e.g., 10 panelists) agreed with the challenge.
Each panelist was limited to one challenge
during the live meeting.
In the interest of brevity and relevance, six of
the 24 considered scenarios are presented in
Part 1 of this article. Part 2 of the article will
present another five scenarios that were
discussed. These selected scenarios were
chosen by the first author (B.E.S.).
Statistical Analysis
For comparing three or more groups,
Friedman’s test was used to rank the data in
each set from high to low. Each set of data was
ranked separately. The value of the Friedman
statistic was calculated from the sums of the
ranks and sample sizes. Dunn’s multiple
comparison post-test was utilized to compare
the difference in the sum of ranks between data
columns. The calculation of the P-value takes
into account the number of comparisons.
Statistical analysis was performed with
GraphPadPrism version 5.00 for Windows
(GraphPad Software, San Diego CA, USA).
Classification of Experimental Evidence
Supporting a Therapeutic Option
Recommendations from the Agency for Health
Care Policy Research (AHCPR) [2] were used to
grade the experimental evidence as it relates to
therapeutic recommendations in each case
study. The categories of evidence include:
level 1a: evidence from meta-analysis of
randomized controlled trials (RCTs); level 1b:
evidence from one or more RCT; level 2a:
evidence from one or more controlled trials
(without randomization); level 2b: evidence
obtained through other well-designed studies
(quasi-experimental); level 3: evidence from
nonexperimental studies (descriptive studies
such as comparative or correlation studies or
case–control studies); level 4: expert committee
opinions, clinical experience.
Preliminary recommendations for
treatments were made using the best available
evidence extracted from published literature.
The strengths of recommendations were graded
as follows: grade A: category 1 evidence; grade
B: category 2 evidence or extrapolation from
category 1 evidence; grade C: category 3
evidence or extrapolation from category 1 or
category 2 evidence; grade D: category 4
evidence or extrapolation from category 2 or
category 3 evidence.
Where definitive scientific evidence was
lacking, ‘‘expert opinion’’ and consensus (e.g.,
the community standard) were used for
suggested recommendations for key practical
issues.
RESULTS
Case Scenario 1: Psoriasis and HPV-
Induced Cervical or Anogenital Dysplasia
The HPV has a role in many diseases, but the
most infamous is cervical cancer. In a study of
3,607 women with cervical cancer, HPV DNA
was detectable in 92.5% (grade C evidence) [3];
however, genotypes 16 and 18 comprise 71% of
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those cases. In addition, HPV is widely
prevalent in the worldwide population.
The presence of HPV DNA has been
demonstrated in up to 90% of the lesional
skin scrapings of psoriasis patients, and it has
been suggested that HPV produces antigens that
stimulate psoriatic disease (grade D evidence)
[4]. In a case study, Rust et al. suggested a link
between psoriasis, light exposure, and HPV in
the development of cutaneous squamous cell
carcinoma (SCC), as a patient with psoriasis
treated extensively with ultraviolet (UV)
therapy was found to have HPV serotypes 12
and 17 in some of her cutaneous SCCs (grade D
evidence) [5]. Additional patients with psoriasis
who were treated with psoralen UVA (PUVA)
therapy and methotrexate were found to have
HPV-positive SCCs, but the overall copy
number and replication activity was low
(grade D evidence) [6]. The cumulative effects
of UV exposure and immunosuppression must
also be considered.
As many of the current psoriasis therapies are
immunosuppressants or immunomodulators,
selection of an agent for a patient with psoriasis
with cervical or anogenital dysplasia is
complicated, but there are no specific data
addressing this scenario. Retinoids have been
tested in cervical intra-epithelial neoplasia (CIN)
and were not effective in preventing disease
progression (grade A evidence) [7]. A recurrence
of condylomata acuminata and a flare of pre-
existing genital lesions have been reported with
etanercept and infliximab, respectively (grade D
evidence) [8]. A randomized, placebo-controlled
clinical trial evaluating etanercept for pediatric
psoriasis also found a higher incidence of skin
papillomas/warts; a total of 16 lesions in the
treatment group as compared to 0 in the placebo
group (grade A evidence) [9].
In light of these data, there is some
consensus that tumor necrosis factor alpha
(TNF-a)-inhibitors may augment the risk of
HPV-induced verruca vulgaris and perhaps
condylomata acuminata. There are no reports
on methotrexate-induced HPV disease. Further,
there are no data regarding the effect of
ustekinumab on HPV. Another consideration
is the use of the recombinant HPV vaccine that
has selective efficacy against HPV types 6, 11,
16, and 18 (grade A evidence) [10]. Some
practitioners suggest that prior to treating
psoriasis or psoriatic arthritis with an
immunosuppressive medication, it may be
prudent to administer this vaccine to younger
patients without a history of demonstrated HPV
infection, but the data supporting this
contention are completely lacking.
Discussion
The panel recognized that genital HPV disease
typically will be detected by gynecologist/
obstetricians rather than dermatologists, but
these clinicians may not recognize or report
associations with psoriasis and its therapy.
Therefore, the literature may not be sufficient
at this point. For most psoriasis therapies, an
annual examination by a gynecologist is not
even recommended. Many of the panelists agreed
that there is an increase in warts, molluscum
contagiosum, and herpes zoster in patients
treated with TNF-a inhibitors, although this
also could apply to other immunosuppressant
therapies.
The panelists ranked the following as top
treatments for HPV-induced cervical or
anogenital dysplasia: narrowband UVB therapy,
UV phototherapy ? acitretin, acitretin alone,
broadband UVB therapy, methotrexate, PUVA,
acitretin ? a biologic agent, a topical steroid,
methotrexate ? a TNF-a inhibitor, and a topical
steroid ? calcipotriene. While some of these
choices represent a higher risk proposition
(e.g., methotrexate ? a TNF-a inhibitor), each
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remains a viable option in the right setting.
Figure 2 presents the final results of the voting
process.
Treatment Challenges: None.
Case Scenario 2: Concomitant Psoriasis
and Systemic Lupus Erythematosus
Cases of concomitant psoriasis with systemic
lupus erythematosus (SLE) are rare, occurring in
only 0.69% of patients with psoriasis and
1.1% of patients with SLE (grade C evidence)
[11]. However, subacute cutaneous lupus
erythematosus (SCLE) may be mistaken for
psoriasis and can coexist with SLE (grade C
evidence) [12]. In either case, despite its
therapeutic uses in psoriasis, phototherapy is a
major concern. Regardless, no published studies
exist to guide therapeutic recommendations.
For psoriasis, methotrexate has well-
documented efficacy (grade A evidence) [13].
In SLE, methotrexate decreases the need for
steroids and is therapeutic in reducing revised
Systemic Lupus Activity Measure (SLAM-R)
scores (grade A evidence) [14].
Acitretin is a psoriasis therapy that has been
tested in SLE. For patients with predominantly
cutaneous SLE, acitretin has been successful
in completely clearing psoriasis in 15 of
20 patients (grade B evidence) [15]. In a
separate study, acitretin was found to improve
cutaneous lesions in 46% of patients (grade B
evidence) [16].
Cyclosporine has an established role in
psoriasis, but it is rarely utilized in SLE due to
potential renal toxicity. This agent may be of
limited use as a second-line therapy (grade B
evidence) [17] or in the settings of lupus-related
thrombocytopenia (grade C evidence) [18] and
hemolytic anemia (grade D evidence) [19].
All of the TNF-a agents have significant roles
in the treatment of psoriasis and there are a few
case reports of benefit in SLE and lupus
nephritis (grade D evidence) [20]. However,
these therapies have an accepted risk of drug-
induced SLE (grade D evidence) [21].
Ustekinumab presents another option given its
success in psoriasis, but there are no published
studies describing its use in SLE.
For SLE, azathioprine has a long history of
use, especially for lupus nephritis (grade B
evidence) [22, 23]. Azathioprine also has
efficacy in psoriasis, with 55% of patients
clearing at least 75% of their psoriasis over a
mean of 12 months of therapy, although the
supporting literature is over 30 years old (grade
B evidence) [24, 25]. Mycophenolate mofetil has
growing support as an alternative to
azathioprine or as a supplementary medication
in SLE and lupus nephritis (grade C evidence)
[26]. In addition, there is one open-label study
demonstrating modest benefit in psoriasis with
22% of patients reaching a 75% reduction in the
Psoriasis Area and Severity Index (PASI) score
after 12 weeks (grade B evidence) [27].
Fig. 2 Final results of the voting on case scenario 1, psoriasis
with HPV-induced cervical or anogenital dysplasia. a denotes
P\0.05 compared withUVB-NB therapy; b denotesP\0.05
compared with UV ? acitretin therapy; c denotes P\0.05
compared with acitretin therapy; d denotes P\0.05 compared
with UVB-BB therapy; e denotes P\0.05 compared with
MTX therapy.HPV human papilloma virus;MTXmethotrex-
ate;TNFI tumor necrosis factor inhibitor;Top topical;UVB-BB
broadband ultraviolet B therapy; UVB-NB narrowband ultra-
violet B therapy
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Hydroxychloroquine also has efficacy in
cutaneous lupus, with 50% of patients
experiencing improvement (grade B evidence),
but its utility in psoriasis is questionable [16].
There is one report of the successful treatment
of psoriasis and SCLE with hydroxychloroquine
(grade D evidence) [28]. Yet, there are other
reports of hydroxychloroquine causing
worsening of psoriasis or pustular flares (grade
D evidence) [29, 30].
Discussion
Panelists shared their individual experience
with these rare cases. One stated that he uses
TNF-a inhibitors in patients with SLE without
difficulty and that the combination with
hydroxychloroquine could be considered to
reduce the formation of antibodies against the
drug, although there are no published data to
support this contention. Another shared the
experience that the TNF-a-induced lupus-like
syndromes typically have the skin findings of
SLE, but are less likely to produce renal or
central nervous system (CNS) manifestations.
While a specific antibody pattern for TNF-a-
inhibitor-induced lupus has not been identified,
another panelist noted higher anti-DNA
antibodies in patients treated with infliximab.
These antibodies have been noted in patients
treated with anti-TNF-a agents without any
clinical manifestations suggestive of SLE.
Another suggested the potential of abatacept
as a crossover therapy, as it has been used in
rheumatoid arthritis (RA) and is being evaluated
for the treatment of psoriatic arthritis.
The agents ranked highest for psoriasis and
concomitant SLE were methotrexate, acitretin,
azathioprine, methotrexate ? a TNF-a inhibitor,
hydroxychloroquine, ustekinumab, cyclosporine,
topical steroids ? calcipotriene, and topical
steroids. Figure 3 presents the final results of
voting on this case.
Treatment Challenges: None.
Case Scenario 3: Severe Psoriatic Nail
Disease Causing Functional or Emotional
Impairment
In a group of patients hospitalized for psoriasis, up
to 78% had psoriatic nail disease. Those with nail
findings were significantly older and also a higher
incidence of psoriatic arthropathy (grade C
evidence) [31]. The majority of patients had both
fingernail and toenail involvement with
subungual hyperkeratosis as the most common
abnormality regardless of site. Some of the features
of psoriatic nail disease resemble onychomycosis
and 18% of patients with psoriatic nail disease may
also have positive mycological cultures. While
psoriaticnaildiseasemay be the solemanifestation
of psoriasis, it may still result in significant
impairment to patients.
For limited nail disease, topical approaches
such as corticosteroids, 5-fluorouracil,
calcipotriene, keratolytics, retinoids, and
anthralin produce variable responses and may
require long treatment periods and great patient
adherence to therapy (grade C evidence) [32].
The requirement for consistent long-term use
Fig. 3 Final results of the voting on case scenario 2,
concomitant psoriasis and systemic lupus erythematosus.
a denotes P\0.05 compared with MTX therapy. MTX
methotrexate; TNFI tumor necrosis factor inhibitor
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may deter some patients. Intralesional
corticosteroids also have been implemented
through needle or needle-less methods, but
remain a difficult therapy for patients.
Many patients with nail disease also have
arthritis; thus, treatments are often chosen
for their ability to improve the manifestations
of psoriatic arthritis. Both methotrexate
(grade D evidence) [33, 34] and adalimumab
(grade D evidence) [35] have successfully
treated psoriatic onycho-pachydermoperiostitis
(POPP), a condition that leads to psoriatic
onychodystrophy (connective-tissue thickening
of the distal phalanx and a periostial reaction).
With therapy, both the nail and joint findings
improve significantly, but there is no evidence
for efficacy in isolated nail disease outside of
POPP. Low-dose cyclosporine led to significant
improvement of nail dystrophy in a small set of
patients with psoriatic onychodystrophy,
although the measure for quantifying nail
severity was not described (grade D evidence)
[36]. A larger study supported the utility of
cyclosporine in psoriatic nail disease alone and
in combination with topical calcipotriene
under occlusion (grade B evidence) [37].
Cyclosporine and etretinate have been
compared, with each showing very modest
efficacy, but the 10-week treatment period
examined would be too short to fully evaluate
an adequate response (grade A evidence) [38]. A
large trial using photo-derived nail psoriasis
severity index (NAPSI) scores found significant
reductions with etanercept treatment after a
12-week period as compared with controls
(grade A evidence) [39]. Infliximab also
effectively treats psoriatic nail disease, with
44.7% of patients demonstrating marked
improvement at week 50 (grade A evidence)
[40]. Ustekinumab also improves nail psoriasis,
reducing the NAPSI score by 50% after 24 weeks
of continuous therapy [41].
Discussion
Panelists shared that many of their patients are
able to clear their nail disease or have
a significant improvement with either
conventional systemic or effective biologic
therapies. Some recommended fungal
evaluation for nonresponders to psoriatic
medications. General conclusions were that
the TNF-a inhibitors had the most rigorous
efficacy data, but that many other systemic
medications have the potential to normalize
nails. Concerns for elevated blood pressure or
renal disease may limit cyclosporine exposure
to a limited time period. Given the slow growth
of nails, eventual toxicity was raised as a
potential hindrance to long-term cyclosporine
usage. While the majority of discussion focused
on the use of systemic medications, topical
therapies were recommended as an adjuvant
directed to cuticular disease.
The top-ranked treatments for severe
psoriatic nail disease causing functional or
emotional impairment were adalimumab,
infliximab, etanercept, methotrexate ? a TNF-a
inhibitor, any TNF-a inhibitor with adalimumab
preferred, any TNF-a inhibitor with etanercept
preferred, ustekinumab, methotrexate,
cyclosporine, and intralesional steroids.
Figure 4 presents the final results of voting on
this case.
Treatment Challenges: None.
Case Scenario 4: Psoriasis Therapies That
Potentially Reduce Cardiovascular
Morbidity and Mortality
Hypertension, diabetes, obesity, smoking, and
dyslipidemia are commonly accepted risk
factors for cardiovascular disease (grade B
evidence) [42, 43]. As compared to their age
and sex-matched counterparts, psoriasis
patients are more frequently diagnosed with
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many of those conditions (grade C evidence)
[44]. In general, obesity, hypertension, diabetes,
hyperlipidemia, and smoking are found at a
higher prevalence in the psoriatic population
and the prevalence of each risk factor increases
as the severity of psoriasis increases (grade B
evidence) [45].
The use of systemic therapies or multiple
uses of potent topical corticosteroids have been
correlated with higher rates of diabetes and
atherosclerosis (grade C evidence) [46].
However, psoriasis may be an independent risk
factor for cardiovascular events, specifically
myocardial infarction (grade B evidence) [45].
This risk may arise from multiple different
factors. Patients with psoriasis have an
increased incidence of conventional
cardiovascular risk factors such as diabetes,
hypertension, obesity, and smoking, but they
are also treated with multiple medications that
may be dyslipidemic (e.g., corticosteroids,
acitretin, or cyclosporine) or have other
cardiovascular implications. In addition,
chronic and uncontrolled inflammation from
psoriatic disease may be related to endothelial
dysfunction that increases cardiovascular risk.
With this new perspective on psoriasis, this
discussion examined the role of psoriasis
treatments in altering psoriasis comorbidities
or overall cardiovascular risk.
Many studies in the RA population have
delved into the assessment of cardiovascular
risk. C-reactive protein (CRP), a measure of
systemic inflammation, has been the most
predictive marker for cardiovascular-related
mortality in patients with RA (grade C
evidence) [47]. There is evidence for the role
of systemic inflammation in cardiovascular risk
as these patients have more unrecognized
myocardial infarctions as compared to
controls, and significantly more events in the
2 years immediately preceding the diagnosis of
RA (grade B evidence) [48]. This suggests that
systemic inflammation can damage the vascular
endothelium and have cardiac consequences
well before the joint manifestations of RA. In
treating RA, methotrexate has been associated
with a decreased risk for acute myocardial
infarction, but both oral corticosteroids and
biologic agents (etanercept, infliximab, and
anakinra) have significantly increased the risk
(grade C evidence) [49]. However, another
study found that biologics (adalimumab,
etanercept, infliximab, and anakinra) were
only associated with increased risks when used
in combination with other immunosuppressants,
and that cytotoxic immunosuppressive
agents (e.g., azathioprine, cyclosporine) and
oral corticosteroids maintained a significantly
elevated risk for cardiovascular events (grade C
evidence) [50]. The Consortium of Rheumatology
Researchers of North America (CORRONA) has
developed a RA registry of over 10,000 patients.
From this cohort, the incidence of
cardiovascular events in patients exposed
Fig. 4 Final results of the voting on case scenario 3, severe
psoriatic nail disease causing functional or emotional impair-
ment. a denotes P\0.05 compared with adalimumab
therapy; b denotes P\0.01 compared with inﬂiximab
therapy; c denotes P\0.05 compared with etanercept
therapy; d denotes P\0.05 compared with MTX ? TNFI
therapy; e denotes P\0.05 compared with TNFI-ada-
limumab preferred therapy. MTX methotrexate; pref pre-
ferred; TNFI tumor necrosis factor inhibitor
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specifically to TNF-a inhibitors is 0.51 events/
1,000 patient years, but TNF-naive patients have
a higher incidence with 0.75 events/1,000
patient years. Duration of exposure is another
contributing factor, as a longer period of
exposure to TNF-inhibitors ([1 year) correlates
with the greatest protection (grade B evidence)
[51].
For individual therapies, methotrexate has
the most evidence in psoriasis and may be able
to reduce the incidence of vascular disease. A
study of patients with psoriasis on methotrexate
therapy demonstrated a significantly reduced
risk of vascular disease compared to subjects
who were not prescribed methotrexate (grade C
evidence) [52]. This effect was most notable
when methotrexate was given at a low
cumulative dose and was further enhanced by
the concomitant use of folic acid. The proposed
mechanism of risk reduction is the ability
of methotrexate to decrease chronic
inflammation. Those requiring higher doses of
methotrexate were also found to receive a
benefit, but they may represent long-standing
and more severe systemic inflammation,
accounting for the difference in benefit as
compared with patients receiving lower doses.
As those with lower doses benefit most, early
treatment with methotrexate may be effective
in decreasing cardiovascular mortality. In
addition, the use of folic acid may act to
reduce hyperhomocysteinemia, which may be
a separate contributor to vascular disease risk.
Etanercept treatment in patients who are
obese and diabetic led to significant reductions
in systemic inflammatory markers, such as CRP
and interleukin-6 (IL-6), but was unable to
affect vascular reactivity or insulin sensitivity
(grade A evidence) [53]. In patients with the
metabolic syndrome, etanercept showed similar
effects with its reduction of CRP, IL-6, and
fibronectin, but did not alter insulin sensitivity
or body composition (grade A evidence) [54].
Etanercept also has been shown to lower the
CRP of prospectively treated patients with
moderate-to-severe psoriasis [55].
In patients with RA refractory to infliximab,
short-term adalimumab therapy significantly
improved endothelial vasodilatory response
and reduced CRP levels (grade C evidence)
[56]. In a recent study, both adalimumab and
infliximab were shown to improve endothelial
function, although common carotid artery
intima-medial thickness did not change
(grade B evidence) [57]. However, these
patients were also on other disease-modifying
antirheumatic drugs (DMARDs), which does not
allow for conclusions regarding an isolated TNF-
a-inhibitor effect. Adalimumab has also been
shown to increase high-density lipoprotein
(HDL) levels while decreasing low-density
lipoprotein (LDL), thus creating a favorable
cardiovascular risk profile in patients with RA
(grade A evidence) [58].
Infliximab alone exerts a rapid and significant
reduction in serum insulin levels and the insulin/
glucose index of patients with RA immediately
following infusion (grade C evidence) [56]. Long-
term infliximab treatment has also been
demonstrated to improve insulin sensitivity
(grade C evidence) [59]. For lipid regulation,
infliximab therapy has been shown to increase
total cholesterol, LDL, and HDL levels without
altering the atherogenic ratio (grade B evidence)
[60]. However, a separate study demonstrated
elevated LDL/HDL and total/HDL-cholesterol
ratios, creating a pro-atherogenic lipid profile
despite the antiinflammatory effect of infliximab
(grade B evidence) [61].
A cohort of patients with RA was studied to
determine the incidence of the first
cardiovascular event in those treated with
either etanercept or adalimumab. There was a
significant decrease in the age-sex adjusted
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incidence rate in the TNF-a-treated patient
group as compared with controls: 14.0/1,000
person years and 35.4/1,000 person years,
respectively (grade B evidence) [62]. These
findings suggest that TNF-a treatments may
have the potential to decrease the risk of a
patient developing a cardiovascular event.
Discussion
Many panelists expressed concern for the lack
of data with various agents on cardiovascular
risks inpatients with psoriasis. The majority of
the data stems from patients with RA.
Regarding the available choices, the panel
agreed that all methotrexate options should
include concomitant folic acid. At the time the
meeting was held, there were no published data
for ustekinumab and its effect on cardiovascular
risk. Since the meeting, pooled data from the
phase 2 and 3 trials of ustekinumab have shown
the drug to have neither a positive or negative
effect on major cardiovascular risks [62].
Additional data were presented at the meeting
showing that ustekinumab was able to decrease
CRP values in patients with psoriasis and had
improved efficacy for joint symptoms in those
with CRP levels elevated to[0.4 mg/dL prior to
therapy (grade A evidence) [63, 64]. However, a
poster presentation for another IL-12/23 inhibitor
that is structurally similar to ustekinumab
(ABT-874 or briakinumab), suggested that drugs
that target the p40 subunit of IL-12/23 may
increase the risk of major adverse cardiovascular
events [65]. Many choices do not have any data
for cardiovascular risk (e.g., phototherapy,
alefacept alone or in combination with
methotrexate); a recognized limitation to the
voting.
The panelists voted to include the following
treatments as psoriasis therapies that potentially
reduce cardiovascular morbidity and mortality:
methotrexate ? TNF-a inhibitor, methotrexate,
TNF-a-inhibitor alone, any TNF-a inhibitor
with etanercept preferred, any TNF-a
inhibitor with adalimumab preferred, any
TNF-a inhibitor with infliximab preferred,
methotrexate ? alefacept, ustekinumab,
cyclosporine, narrowband UVB phototherapy.
It should be noted that cyclosporine may alter
lipid profiles unfavorably, and therefore remains
a more complex treatment decision in this
setting. Figure 5 shows the final results of voting.
Treatment Challenges
(1) Removal of ustekinumab. At the time of this
meeting in 2009, ustekinumab was not
approved or available in the US for the
treatment of psoriasis and panelists expressed
concern that there was extremely limited data
on its use. Documented cardiovascular events
had also occurred in the treatment group in the
early trials (two myocardial infarctions and one
stroke; grade A evidence) [66], although there
was only one patient who experienced a stroke
in the phase 3 trials (grade A evidence) [67]. The
Fig. 5 Final results of the voting on case scenario 4,
psoriasis therapies that potentially reduce cardiovascular
morbidity and mortality. a denotes P\0.05 compared
with MTX-TNFI therapy; b denotes P\0.01 compared
with MTX therapy; c denotes P\0.05 compared with
TNFI therapy; d denotes P\0.01 compared with TNFI
(etanercept preferred) therapy; e denotes P\0.01 com-
pared with TNFI (adalimumab preferred) therapy. MTX
methotrexate; pref preferred; TNFI tumor necrosis factor
inhibitor; UVB-NB narrowband ultraviolet B therapy
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only beneficial cardiovascular evidence was a
potential decrease in CRP.
However, the group argued that many other
choices voted on had even less data or no data
regarding cardiovascular risk factors, and
ustekinumab remained on the list as a
therapeutic option, with 11 participants voting
to keep it as opposed to two voting to remove it.
(2) Removal of narrowband UVB therapy.
The suggestion to remove narrowband UVB
therapy was based on a lack of evidence for
reduction in cardiovascular mortality. However,
many panelists argued that it does not have
documented increases in cardiovascular risk and
that it can function as a psoriasis treatment
without cardiovascular harm. The panel voted
to allow phototherapy to remain on the list,
with seven voting to allow it as a treatment
option and six voting to remove it.
Case Scenario 5: Older Patients (‡65 Years
of Age) with Psoriasis
Geriatric medicine identifies itself as serving
patients typically C65 years of age, a fast-
growing subset of the population (grade C
evidence) [68]. From 1950 to 2006, the average
annual population growth rate in the US was
1.2%, but 1.5% for those ages 65–74 years and
2.8% for those[75 years. By 2050, 20.7% of the
population is expected to be[65 years of age
(grade C evidence) [69].
Polypharmacy is a significant consideration
in this group, as it increases the risk for adverse
drug events and overall mortality (grade C
evidence) [70]. In addition, the incidence of
multiple medical problems such as mobility
issues, arthritis, stroke, congestive heart failure,
glucose intolerance, hypertension, osteoporosis,
and malignancy increases with age, thereby
influencing which medicines one may
prescribe. Importantly, too, the elderly often
live on fixed incomes and may find the
affordability of the various treatments
prohibitive.
Multiple age-related changes affect the
pharmacokinetics of topical and systemic
medications. With age, shifts in body
composition may affect drug distribution and
half-life, while decreases in renal and liver
function may alter medication metabolism and
clearance. In addition, skin surface changes, such
as reduced hydration of the stratum corneum, a
decreased lipid component, and lowered
microcirculation, may all impact percutaneous
absorption of topical medications (grade C
evidence) [71].
Psoriasis therapy in particular has specific
considerations in the aging population. With
the high incidence of polypharmacy, drug-
induced or drug-exacerbated psoriasis becomes
more prominent. Older patients also face a
range of medical, social, psychological, and
financial stressors that will affect the
availability and efficacy of medications or their
practical use and patient adherence. With these
considerations, one group suggests the use of
topical medications as a first-line therapy,
followed by narrowband UVB therapy. They
reserve the use of methotrexate, acitretin, or
cyclosporine only for patients with severe
psoriasis, as there is a diminished therapeutic
index in the elderly (grade D evidence) [72].
Few therapies have been studied in an elderly
psoriasis population. Pooled data from the
clinical trials of alefacept found similar efficacy
and adverse event profiles in the elderly as
compared to all enrolled psoriasis patients
(grade A evidence) [73]. In patients with RA,
methotrexate metabolic clearance is inversely
proportional to age and further decreases with
declines in creatinine clearance (grade B
evidence) [74]. For psoriasis, methotrexate-
associated myelosuppression may be fatal and
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is more likely to occur in the elderly (grade C
evidence) [75]. The pharmacokinetics of
cyclosporine in organ-transplant recipients
does not differ significantly with age, but the
elderly are still at risk for adverse drug events or
the consequences of polypharmacy (grade B
evidence) [76]. In elderly patients with RA, the
use of TNF-a inhibitors has been associated with
an increased risk of new-onset congestive heart
failure (CHF) or exacerbation of pre-existing
CHF. In those with prior CHF, the risk of death
was fourfold higher in TNF-a users as compared
to methotrexate users (grade B evidence) [77].
Discussion
Overall, the data for specific therapies in the
elderly psoriatic population are limited. In
many of the psoriasis trials, there is an
underrepresentation of elderly patients as they
are often excluded by comorbidities. The elderly
have also experienced a longer duration of
disease, which may affect their health prior to
therapy and alter their response to treatment.
Many panelists agreed that the therapeutic
index is significantly reduced in the elderly.
However, if the age-related concerns or risk
factors are known, then panelists felt that
systemic medications could still be of use in
this population. Methotrexate was offered as an
example, as it is typically efficacious at a lower
dose in the elderly. While this may be due to
age-related reductions in creatinine clearance, if
this is known prior to the start of therapy,
overdoses or adverse events may be avoided.
Attention to polypharmacy is a requirement, as
drug interactions may be more likely.
In contrast to methotrexate, other panelists
supported the use of TNF-a agents as they may
present a safer option when used in the
appropriate subset of patients. Of the TNF-a
agents, etanercept was highlighted for having
the shortest half-life. Acitretin was also
discussed as an option at low doses. In respect
to disease severity, some proposed having the
same treatment modalities available regardless
of age. In addition, as many young patients
have multiple conditions, comorbidities may
dictate treatment rather than age.
Specific vaccinations are also recommended
for elderly patients. The efficacy of these vaccines
in the context of systemic psoriasis therapies
remains debatable. Regardless, the panelists
agreed that live vaccination should be avoided
while a patient receives immunosuppressive
therapy.
Top-ranked treatments for older patients
with psoriasis include methotrexate, any TNF-a
inhibitor with etanercept preferred, any TNF-a
inhibitor with adalimumab preferred, acitretin,
etanercept, narrowband UVB phototherapy, UV
phototherapy ? acitretin, methotrexate ? TNF-
a inhibitor, infliximab, and alefacept. Figure 6
presents the final results of voting.
Treatment Challenges: None.
Fig. 6 Final results of the voting on case scenario 5, older
patients (C65 years of age) with psoriasis. a denotes
P\0.01 compared with MTX therapy; b denotes
P\0.01 compared with TNFI-etanercept preferred ther-
apy; c denotes P\0.05 compared with TNFI-adalimumab
preferred therapy; d denotes P\0.05 compared with
acitretin therapy; e denotes P\0.05 compared with
etanercept therapy. MTX methotrexate; pref preferred;
TNFI tumor necrosis factor inhibitor; UV ultraviolet;
UVB-NB narrowband ultraviolet B therapy
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Case Scenario 6: Severe Scalp Psoriasis
that is Unresponsive to Topical Therapy
Psoriasis has a well-known impact on both
mental health and quality of life (grade C
evidence) [78, 79]. Scalp psoriasis does not
differ, as up to 57% of patients experience
psychological and social distress relating to
sensations of scalp itch and scaling (grade C
evidence) [80]. Many patients will face
involvement of the majority of the scalp
surface, and up to 86% will have other bodily
areas of involvement.
For the TNF-a inhibitor class of therapeutics,
both etanercept and infliximab have scalp-
specific data. In one study, etanercept
improved the Physician’s Global Assessment
(PGA) scalp psoriasis score by 58% at 12 and
24 weeks (grade B evidence) [81]. Scalp
improvement correlated with a similar
response in the skin; the total body surface
area affected improved by 50–60%. A
randomized, double-blind, placebo-controlled
trial that was underway for etanercept in the
treatment of moderate-to-severe plaque
psoriasis in patients with scalp disease at the
time of the live meeting in 2009 has since been
completed [82]. It showed that at a dose of
50 mg twice weekly, etanercept improved the
Psoriasis Scalp Severity Index (PSSI) score by
87% by week 12 compared with a 20%
improvement in the placebo group (grade A
evidence) [83]. Even when the dose was reduced
to 50 mg once weekly from weeks 12–24, the
PSSI score improvement was maintained, while
patients who were switched from placebo to
etanercept 50 mg twice weekly had a 79% mean
improvement in their PSSI score. For infliximab,
subanalysis of three RCTs demonstrated
consistently high efficacy for scalp psoriasis
with up to 79–85% of patients reaching a
PASI 75 in the head and neck region (grade A
evidence) [84]. The efficacy on the trunk was
nearly equivalent, but slightly lower on the
extremities. Therapy with alefacept induced
16.7% of patients to reach a scalp PGA of
‘‘clear/almost clear’’ after 16 weeks of therapy
(grade B evidence) [85]. A second course of
therapy was able to increase the proportion of
responders to 26.7%.
Other systemic agents such as methotrexate,
cyclosporine, and intralesional corticosteroids
do not have studies dedicated to scalp
treatment. From the nonsystemic options, the
excimer laser has produced significant
responses when used in combination with
manual hair separation or a hair blower device
to increase the visible scalp surface area (grade B
evidence) [86, 87]. Forty-nine percent of
patients were able to clear greater than 95%
of their scalp disease in an average of
21 treatments [87]. However, phototoxicity
around the ears and neck was a common
adverse event of excimer laser therapy.
Grenz ray therapy has also been shown to
clear scalp psoriasis in up to 78% of patients and
a combination with topical corticosteroids
induced a longer remission period (grade B
evidence) [88, 89].
Discussion
Many panelists stated that the scalp and the
rest of the integument should be considered
equivalent and agreed that no modifications
in the therapeutic regimen were necessary
for scalp-specific treatment. One panelist
noted that for the few patients with
scalp-only involvement, it might be more
difficult to attain health insurance approval
for costlier systemic medications based
on the relatively low body-surface area
involvement.
Some panelists noted that they had seen
improvement with hair removal on the scalp or
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the beard area, which may be secondary to the
increased exposure to solar-derived UV light.
Top-ranked treatments for severe scalp
psoriasis unresponsive to topical therapies
were any TNF-a inhibitor with adalimumab
preferred, adalimumab alone, any TNF-a
inhibitor with etanercept preferred, etanercept,
methotrexate, methotrexate ? TNF-a inhibitor,
infliximab, cyclosporine, and intralesional
steroids. The final results of the voting are
presented in Fig. 7.
Treatment Challenges: None.
DISCUSSION
Clinical trials of traditional systemic and
biologic treatments for psoriasis exclude a
significant proportion of patients with either
comorbidities or clinical states that present risk.
The Delphi method was used to clarify the
therapeutic approach to 24 important and
complex clinical scenarios, which were assigned
to a group of expert panelists for detailed
review prior to presentation at a live meeting.
Six of these scenarios are presented here;
another five scenarios are presented in Part 2.
The iterative and anonymous voting process of
this method depends on an unbiased view of
the available clinical data and leads to more
objective consensus. This exercise is not meant
to be the ‘‘final word’’ with regard to therapy for
these types of patients, and the numerical
‘‘precision’’ of the rankings should not mislead
the reader into believing we have created
a completely valid ‘‘top-10 list.’’ In fact, for
example, with reference to any specific patient,
the treatment option ranked first might not be
‘‘better’’ than those ranked either 5th or 10th.
Instead, the final rankings should be viewed as
guidance for practical, potentially effective, and
likely safe treatment in a majority of instances.
Of course, medical appropriateness of any given
therapeutic modality will vary from patient to
patient. Because the Delphi method does not
introduce better data for a given topic, it cannot
produce an idealized outcome. In this vein, the
process we have utilized selects rational
treatment choices for each clinical scenario,
but these choices often are not supported
by rigorous studies. At the very least, this
evidence-based approach relying on anonymous
consensus is a more objective tool for reaching
consensus.
An important limitation of this process is
that new highly relevant information may be
published subsequent to the exercise, which in
this case was conducted in 2009. Since that
time, for example, efalizumab was voluntarily
removed from the US market due to the risk of
progressive multifocal leukoencephalopathy
(PML) [90, 91].
Another limitation is that some treatment
options, such as UV phototherapy, are
performed in different settings and guided
by different protocols. Specifically, UV
phototherapy may be conducted in an office,
at a hospital, or at home. Some practitioners
might consider tanning beds at commercial
Fig. 7 Final results of the voting on case scenario 6, severe
scalp psoriasis that is unresponsive to topical therapy.
a denotes P\0.05 compared with TNFI-adalimumab
preferred therapy; b denotes P\0.05 compared with
adalimumab therapy. MTX methotrexate; pref preferred;
TNFI tumor necrosis factor inhibitor
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facilities a viable alternative to a practice or
home-based approach. Regardless, we assumed
that the choice for ‘‘UV phototherapy’’
encompasses the generic approach of treating
psoriasis with UV light. The reader is
encouraged to apply his or her knowledge,
style, and experience in determining the
generalizability of recommendations for
the broader term ‘‘UV phototherapy’’ to the
specific types of this modality.
Another potential limitation is conflict of
interest among the panelists. Our selection of
panelists was guided by their extensive
experience with the use of all modalities for
the treatment of psoriasis. Undeniably, this
group has an extraordinarily large base of
patients, and thus experience, on which to
guide their opinions. Importantly, the results
of the voting for many of the scenarios
indicated a great deal of objectivity in the
analysis. In fact, many of the biologic agents
(e.g., adalimumab, alefacept, etanercept,
infliximab, ustekinumab) were rated lowly. On
the other hand, for certain scenarios, older
conventional modalities such as UV
phototherapy, methotrexate, acitretin, and
cyclosporine were selected as the most
appropriate therapeutic choices. The conflicts
of interests for this large panel are extensive, but
also are quite broad and diverse both with
regard to each individual panelist and across the
entire group. The authors think this resulted in
a very fair process that, in fact, treated biologic
therapies quite appropriately.
Finally, the panel of experts is derived
entirely from the US. The treatment options
are based on what is locally available in the US,
and therefore are sometimes not relevant to the
rest of the world.
The goal in performing this Delphi exercise
was to help clinicians in practice benefit from
these consensus opinions, offering guidance
when presented with patients displaying
similar challenging clinical scenarios, and
allowing for the use of specific treatment
approaches that are effective and safe.
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